Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) -December 11, 2023 at 06:15 am | MarketScreener

Source: Buzz FX / 11 Dec 2023 00:26:29   America/Chicago